SCYNEXIS, Inc. is progressing on its second-generation antifungal SCY-247, having initiated a Phase 1 trial in December 2024, with results expected in Q3 2025. The company also plans to present data ...
SCYNEXIS (SCYX) to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasis Scynexis will promptly wind-down and terminate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results